Browsing by Author "Drulovic, J. (6603831498)"
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Prevalence of multiple sclerosis in Belgrade, Yugoslavia(2001) ;Pekmezovic, T. (7003989932) ;Jarebinski, M. (7003463550) ;Drulovic, J. (6603831498) ;Stojsavljevic, N. (6603086728)Levic, Z. (7003341242)Objectives - To estimate the distribution of multiple sclerosis in the Belgrade population. Methods - All persons who were affected and/or died from multiple sclerosis (Poser's criteria), with residence in the Belgrade region had been collected from January 1, 1985 to December 31, 1996. Prevalence was adjusted by direct method, using world population. Results - From 1985 to 1996, 823 patients were suffering from multiple sclerosis. Sex ratio was 1:1.9. The mean age at onset was 32.2 ± 9.8 years. A relapsing-remitting course of multiple sclerosis was reported in 50.7% patients, secondary progressive in 36.4% patients, and primary progressive in 12.9% patients. On December 31, 1996, age-adjusted prevalence of multiple sclerosis in Belgrade was 41.5/100,000, 28.2/100,000 for males, and 54.1/100,000 for females. During the period studied, statistically highly significant increasing trend of multiple sclerosis prevalence was observed (P = 0.0001). Conclusions - According to findings presented in this study, Belgrade is an area with high prevalence of multiple sclerosis. - Some of the metrics are blocked by yourconsent settings
Publication Prevalence of multiple sclerosis in Belgrade, Yugoslavia(2001) ;Pekmezovic, T. (7003989932) ;Jarebinski, M. (7003463550) ;Drulovic, J. (6603831498) ;Stojsavljevic, N. (6603086728)Levic, Z. (7003341242)Objectives - To estimate the distribution of multiple sclerosis in the Belgrade population. Methods - All persons who were affected and/or died from multiple sclerosis (Poser's criteria), with residence in the Belgrade region had been collected from January 1, 1985 to December 31, 1996. Prevalence was adjusted by direct method, using world population. Results - From 1985 to 1996, 823 patients were suffering from multiple sclerosis. Sex ratio was 1:1.9. The mean age at onset was 32.2 ± 9.8 years. A relapsing-remitting course of multiple sclerosis was reported in 50.7% patients, secondary progressive in 36.4% patients, and primary progressive in 12.9% patients. On December 31, 1996, age-adjusted prevalence of multiple sclerosis in Belgrade was 41.5/100,000, 28.2/100,000 for males, and 54.1/100,000 for females. During the period studied, statistically highly significant increasing trend of multiple sclerosis prevalence was observed (P = 0.0001). Conclusions - According to findings presented in this study, Belgrade is an area with high prevalence of multiple sclerosis. - Some of the metrics are blocked by yourconsent settings
Publication The epidemiology of multiple sclerosis in Europe(2006) ;Pugliatti, M. (6603827112) ;Rosati, G. (7102230881) ;Carton, H. (7005058948) ;Riise, T. (7006303077) ;Drulovic, J. (6603831498) ;Vécsei, L. (35452449900)Milanov, I. (55865025400)Multiple sclerosis (MS) is a chronic and potentially highly disabling disorder with considerable social impact and economic consequences. It is the major cause of non-traumatic disability in young adults. The social costs associated with MS are high because of its long duration, the early loss of productivity, the need for assistance in activities of daily living and the use of immunomodulatory treatments and multidisciplinary health care. Available MS epidemiological estimates are aimed at providing a measure of the disease burden in Europe. The total estimated prevalence rate of MS for the past three decades is 83 per 100 000 with higher rates in northern countries and a female:male ratio around 2.0. Prevalence rates are higher for women for all countries considered. The highest prevalence rates have been estimated for the age group 35-64 years for both sexes and for all countries. The estimated European mean annual MS incidence rate is 4.3 cases per 100 000. The mean distribution by disease course and by disability is also reported. Despite the wealth of epidemiological data on MS, comparing epidemiological indices among European countries is a hard task and often leads only to approximate estimates. This represents a major methodological concern when evaluating the MS burden in Europe and when implementing specific cost-of-illness studies. © 2006 EFNS. - Some of the metrics are blocked by yourconsent settings
Publication The epidemiology of multiple sclerosis in Europe(2006) ;Pugliatti, M. (6603827112) ;Rosati, G. (7102230881) ;Carton, H. (7005058948) ;Riise, T. (7006303077) ;Drulovic, J. (6603831498) ;Vécsei, L. (35452449900)Milanov, I. (55865025400)Multiple sclerosis (MS) is a chronic and potentially highly disabling disorder with considerable social impact and economic consequences. It is the major cause of non-traumatic disability in young adults. The social costs associated with MS are high because of its long duration, the early loss of productivity, the need for assistance in activities of daily living and the use of immunomodulatory treatments and multidisciplinary health care. Available MS epidemiological estimates are aimed at providing a measure of the disease burden in Europe. The total estimated prevalence rate of MS for the past three decades is 83 per 100 000 with higher rates in northern countries and a female:male ratio around 2.0. Prevalence rates are higher for women for all countries considered. The highest prevalence rates have been estimated for the age group 35-64 years for both sexes and for all countries. The estimated European mean annual MS incidence rate is 4.3 cases per 100 000. The mean distribution by disease course and by disability is also reported. Despite the wealth of epidemiological data on MS, comparing epidemiological indices among European countries is a hard task and often leads only to approximate estimates. This represents a major methodological concern when evaluating the MS burden in Europe and when implementing specific cost-of-illness studies. © 2006 EFNS.